About
Investor Inquiries: ICR WestwickeMike Piccinino , CFA OrganoIR@westwicke.com Press and Media Inquiries: OrganogenesisLori Freedman lfreedman@organo.com
Source:
2022 GlobeNewswire, Inc., source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.31 USD | -5.33% | -7.97% | -43.52% |
May. 02 | Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis | CI |
Feb. 29 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
About
Investor Inquiries: ICR WestwickeMike Piccinino , CFA OrganoIR@westwicke.com Press and Media Inquiries: OrganogenesisLori Freedman lfreedman@organo.com
Source:
2022 GlobeNewswire, Inc., source
1st Jan change | Capi. | |
---|---|---|
-43.52% | 323M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |